HIPRA participated as a Silver Sponsor at the ICARE Congress, held from May 20th to 24th in Ghent, Belgium. The event brought together over 700 attendees from 45 different countries, specializing in exotic and companion animals.

During the congress, our colleagues Eva Perozo, researcher of preclinical and clinical trials at HIPRA, and Sandra Gascón, Global Product Manager of rabbit vaccines, presented three scientific posters related to our new vaccine against Rabbit Haemorrhagic Disease (RHD), YURVAC® RHD.

Two oral communications were also presented, which generated a lot of interest with over 400 attendees. The first was delivered by Filipe Pinto, sales representative of HIPRA Portugal and PhD student, where he emphasized the difficulty in the antemortem diagnosis of RHD and its potential repercussions such as underdiagnosis in companion rabbits. With the presentation titled "The reliable antemortem diagnosis of rabbit haemorrhagic disease (RHD)", new tools were offered that could be applied in the antemortem diagnosis of the disease.

The second oral communication, "YURVAC® RHD vaccine against RHDV and RHDV2," was presented by Eva Perozo. During the presentation, all efficacy study results used for the registration of YURVAC® RHD with the European Medicines Agency (EMA) were shown, highlighting the very good protective results against highly virulent strains of RHDV2. These results make YURVAC® RHD the only recombinant vaccine indicated for protection against highly virulent strains of RHDV2. Additionally, it was demonstrated how we produce YURVAC® RHD in an innovative and animal welfare-committed manner, using yeast as a technological platform to produce the active substance in the form of Virus Like-Particles (VLPs).